Pharmacy Medical News about Economics, Pharmaceutical

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A Cost-Effectiveness Analysis to Illustrate the Impact of Cost Definitions on Results, Interpretations and Comparability of Pharmacoeconomic Studies in the US
PharmacoEconomics, 09/18/09

Tunis SL – Explicitly addressing the cost–definition issue can help provide meaningful cost–effectiveness data to payers for policy development and management of healthcare expenditures. It can also help move the pharmacoeconomics and outcomes research fields forward in terms of both methodology and practical application.

<< Previous
Current progress in the pharmacological therapy of fibromyalgia

Next >>
The use of intraocular corticosteroids

Economic Evaluation and Cost-Effectiveness Thresholds: Signals to Firms and Implications for R&D Investment and Innovation
PharmacoEconomics, 10/07/09 Relevance Score: 67%

30 Years of Pharmaceutical Cost-Utility Analyses: Growth, Diversity and Methodological Improvement
PharmacoEconomics, 10/13/09 Relevance Score: 66%

Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings
Health Policy and Planning, 10/21/09 Relevance Score: 65%

Financial Risk of the Biotech Industry versus the Pharmaceutical Industry
Applied Health Economics and Health Policy, 10/20/09 Relevance Score: 64%

Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective: Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide
PharmacoEconomics, 10/13/09 Relevance Score: 64%